Organ-specific off-target effects of Pim/ZIP kinase inhibitors suggest lack of contractile Pim kinase activity in prostate, bladder, and vascular smooth muscle.

[1]  M. Speakman,et al.  Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. , 2023, European urology.

[2]  J. J. de la Rosette,et al.  Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients , 2023, Frontiers in Pharmacology.

[3]  L. Cardozo,et al.  Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders , 2023, Pharmacological Reviews.

[4]  Zhenbo Wang,et al.  Toxic effects of AZD1208 on mouse oocytes and its possible mechanisms , 2022, Journal of cellular physiology.

[5]  C. Stief,et al.  Inhibition of neurogenic contractions in renal arteries and of cholinergic contractions in coronary arteries by the presumed inhibitor of ADP-ribosylation factor 6, NAV2729 , 2022, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  M. Tzvetkov,et al.  PIM1 Inhibition Affects Glioblastoma Stem Cell Behavior and Kills Glioblastoma Stem-like Cells , 2021, International journal of molecular sciences.

[7]  A. Chatterjee,et al.  Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication , 2021, Oncotarget.

[8]  M. Ezzati,et al.  Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension , 2021, Nature Reviews Cardiology.

[9]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[10]  Martin C Michel,et al.  New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology , 2019, Drug Metabolism and Disposition.

[11]  C. Sutherland,et al.  Rho-associated kinase and zipper-interacting protein kinase, but not myosin light chain kinase, are involved in the regulation of myosin phosphorylation in serum-stimulated human arterial smooth muscle cells , 2019, PloS one.

[12]  L. Kenner,et al.  The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status , 2019, Nature Communications.

[13]  Philip F. Hughes,et al.  Targeting Pim Kinases and DAPK3 to Control Hypertension. , 2018, Cell chemical biology.

[14]  C. Stief,et al.  Long‐term functional outcome analysis in a large cohort of patients after radical prostatectomy , 2018, Neurourology and urodynamics.

[15]  M. Minden,et al.  Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers , 2018, British Journal of Cancer.

[16]  B. Jang,et al.  AZD1208, a pan‐Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3‐L1 adipocytes , 2018, Journal of cellular and molecular medicine.

[17]  R. Touyz,et al.  Vascular smooth muscle contraction in hypertension , 2018, Cardiovascular research.

[18]  T. Haystead,et al.  A Small Molecule Pyrazolo[3,4-d]Pyrimidinone Inhibitor of Zipper-Interacting Protein Kinase Suppresses Calcium Sensitization of Vascular Smooth Muscle , 2016, Molecular Pharmacology.

[19]  R. Tooze,et al.  Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas , 2015, Molecular Cancer.

[20]  M. Konopleva,et al.  The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression , 2015, Oncotarget.

[21]  C. Stief,et al.  Prostatic α1‐adrenoceptors: New concepts of function, regulation, and intracellular signaling , 2014, Neurourology and urodynamics.

[22]  M. Ikebe,et al.  ZIPK is critical for the motility and contractility of VSMCs through the regulation of nonmuscle myosin II isoforms. , 2014, American journal of physiology. Heart and circulatory physiology.

[23]  Allan Wu,et al.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. , 2014, Blood.

[24]  Philip F. Hughes,et al.  Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. , 2013, ACS chemical biology.

[25]  A. Ferguson,et al.  Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. , 2012, Bioorganic & medicinal chemistry letters.

[26]  Jennifer E Amon,et al.  Ca2+-independent contraction of longitudinal ileal smooth muscle is potentiated by a zipper-interacting protein kinase pseudosubstrate peptide. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[27]  F. Schröder,et al.  Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. , 2009, European urology.

[28]  T. Sauerbruch,et al.  Mechanisms of extrahepatic vasodilation in portal hypertension , 2008, Gut.

[29]  I. W. Cheney,et al.  Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. , 2007, Bioorganic & medicinal chemistry letters.

[30]  E. Ihara,et al.  The regulation of smooth muscle contractility by zipper-interacting protein kinase. , 2007, Canadian journal of physiology and pharmacology.

[31]  M. Michel,et al.  α1‐, α2‐ and β‐adrenoceptors in the urinary bladder, urethra and prostate , 2006 .

[32]  T. Haystead,et al.  ZIP kinase, a key regulator of myosin protein phosphatase 1. , 2005, Cellular signalling.

[33]  A. Somlyo,et al.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.

[34]  S. Bojesen,et al.  The link between benign prostatic hyperplasia and prostate cancer , 2013, Nature Reviews Urology.